Identification

Name
Mesoridazine
Accession Number
DB00933  (APRD00610)
Type
Small Molecule
Groups
Approved, Investigational
Description

A phenothiazine antipsychotic with effects similar to chlorpromazine. [PubChem]

Structure
Thumb
Synonyms
  • 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine
  • 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine
  • 2-Methanesulfinyl-10-[2-(1-methyl-piperidin-2-yl)-ethyl]-10H-phenothiazine
  • Mesoridazina
  • Mesoridazine
  • Mesoridazinum
  • Thioridazine Thiomethyl Sulfoxide
  • thioridazine-2-sulfoxide
  • TPS-23
Product Ingredients
IngredientUNIICASInChI Key
Mesoridazine besylateT4G2I958J232672-69-8CRJHBCPQHRVYBS-UHFFFAOYSA-N
Mesoridazine mesilateNot AvailableNot AvailableNot applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Serentil Tab 10mgTablet10 mgOralNovartis1970-12-312000-08-02Canada
Serentil Tab 25mgTablet25 mgOralNovartis1997-08-292001-07-30Canada
Serentil Tab 50mgTablet50 mgOralNovartis1997-08-292001-07-30Canada
International/Other Brands
Lidanar / Lidanil / Serentil
Categories
UNII
5XE4NWM740
CAS number
5588-33-0
Weight
Average: 386.574
Monoisotopic: 386.148654844
Chemical Formula
C21H26N2OS2
InChI Key
SLVMESMUVMCQIY-UHFFFAOYSA-N
InChI
InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
IUPAC Name
2-methanesulfinyl-10-[2-(1-methylpiperidin-2-yl)ethyl]-10H-phenothiazine
SMILES
CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O

Pharmacology

Indication

Used in the treatment of schizophrenia, organic brain disorders, alcoholism and psychoneuroses.

Structured Indications
Not Available
Pharmacodynamics

Mesoridazine, the besylate salt of a metabolite of thioridazine, is a phenothiazine tranquilizer. Pharmacological studies in laboratory animals have established that mesoridazine has a spectrum of pharmacodynamic actions typical of a major tranquilizer. In common with other tranquilizers it inhibits spontaneous motor activity in mice, prolongs thiopental and hexobarbital sleeping time in mice and produces spindles and block of arousal reaction in the EEG of rabbits. It is effective in blocking spinal reflexes in the cut and antagonizes d-amphetamine excitation and toxicity in grouped mice. It shows a moderate adrenergic blocking activity in vitro and in vivo and antagonizes 5-hydroxytryptamine in vivo. Intravenously administered, it lowers the blood pressure of anesthetized dogs. It has a weak antiacetylcholine effect in vitro.

Mechanism of action

Based upon animal studies, mesoridazine, as with other phenothiazines, acts indirectly on reticular formation, whereby neuronal activity into reticular formation is reduced without affecting its intrinsic ability to activate the cerebral cortex. In addition, the phenothiazines exhibit at least part of their activities through depression of hypothalamic centers. Neurochemically, the phenothiazines are thought to exert their effects by a central adrenergic blocking action.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
Absorption

Well absorbed from the gastrointestinal tract.

Volume of distribution
Not Available
Protein binding

4%

Metabolism
Not Available
Route of elimination
Not Available
Half life

24 to 48 hours

Clearance
Not Available
Toxicity

Oral LD50 is 560 ± 62.5 mg/kg and 644 ± 48 mg/kg in mouse and rat, respectively. Symptoms of overdose may include emesis, muscle tremors, decreased food intake and death associated with aspiration of oral-gastric contents into the respiratory system.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineMesoridazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineMesoridazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineMesoridazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Mesoridazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Mesoridazine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Mesoridazine can be increased when it is combined with Abiraterone.Approved
AcebutololMesoridazine may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Mesoridazine.Approved, Illicit
AlgeldrateAlgeldrate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Allopregnanolone.Investigational
AlmagateAlmagate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlmasilateAlmasilate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Mesoridazine.Approved, Investigational
AloglutamolAloglutamol can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Mesoridazine.Approved, Illicit, Investigational
AlprenololMesoridazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineThe therapeutic efficacy of Mesoridazine can be decreased when used in combination with Amantadine.Approved
AmiodaroneThe metabolism of Mesoridazine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Mesoridazine.Approved, Illicit
AmodiaquineThe serum concentration of Mesoridazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amperozide.Experimental
AmphetamineMesoridazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
ApomorphineThe therapeutic efficacy of Mesoridazine can be decreased when used in combination with Apomorphine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Mesoridazine.Approved, Investigational
ArotinololMesoridazine may increase the hypotensive activities of Arotinolol.Approved, Investigational
ArtemetherThe serum concentration of Mesoridazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Mesoridazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Mesoridazine can be increased when it is combined with Artemotil.Experimental
ArtenimolThe serum concentration of Mesoridazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Mesoridazine can be increased when it is combined with Artesunate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Mesoridazine.Approved
AtenololMesoridazine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Mesoridazine can be decreased when combined with Atomoxetine.Approved
AtovaquoneThe serum concentration of Mesoridazine can be increased when it is combined with Atovaquone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Azaperone.Investigational, Vet Approved
AzelastineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Barbital.Illicit
BefunololMesoridazine may increase the hypotensive activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Benzocaine.Approved
BenzphetamineMesoridazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Mesoridazine can be decreased when combined with Betaxolol.Approved
BevantololMesoridazine may increase the hypotensive activities of Bevantolol.Approved
BezitramideMesoridazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BisoprololMesoridazine may increase the hypotensive activities of Bisoprolol.Approved
BopindololMesoridazine may increase the hypotensive activities of Bopindolol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Mesoridazine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Mesoridazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololMesoridazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolMesoridazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Mesoridazine.Approved, Investigational
BupranololMesoridazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Mesoridazine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Mesoridazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Mesoridazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mesoridazine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Mesoridazine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Mesoridazine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Carisoprodol.Approved
CarteololMesoridazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolMesoridazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Mesoridazine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololMesoridazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mesoridazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Mesoridazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorphenamine.Approved
ChlorphentermineMesoridazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Mesoridazine can be increased when it is combined with Chlorproguanil.Investigational
ChlorpromazineThe metabolism of Mesoridazine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Mesoridazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Mesoridazine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Mesoridazine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Mesoridazine.Approved, Vet Approved
CitalopramThe metabolism of Mesoridazine can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Mesoridazine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clidinium.Approved
ClobazamThe metabolism of Mesoridazine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Mesoridazine is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Mesoridazine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clopenthixol.Experimental
CloranololMesoridazine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Mesoridazine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Mesoridazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Mesoridazine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Mesoridazine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Mesoridazine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Mesoridazine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mesoridazine.Approved
Cycloguanil embonateThe serum concentration of Mesoridazine can be increased when it is combined with Cycloguanil embonate.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mesoridazine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Mesoridazine can be increased when it is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Mesoridazine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Mesoridazine can be increased when it is combined with Darunavir.Approved
DelavirdineThe metabolism of Mesoridazine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Mesoridazine.Approved
DesipramineThe metabolism of Mesoridazine can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Mesoridazine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mesoridazine.Approved, Vet Approved
DextroamphetamineMesoridazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Mesoridazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mesoridazine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Mesoridazine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Diethyl ether.Experimental
DiethylpropionMesoridazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mesoridazine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Mesoridazine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Mesoridazine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mesoridazine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Mesoridazine can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Doxepin.Approved
DoxycyclineThe serum concentration of Mesoridazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Mesoridazine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Illicit
DronedaroneThe metabolism of Mesoridazine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Mesoridazine can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Mesoridazine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Mesoridazine.Approved, Investigational
EliglustatThe metabolism of Mesoridazine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Mesoridazine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Entacapone.Approved, Investigational
EpanololMesoridazine may increase the hypotensive activities of Epanolol.Experimental
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Mesoridazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Mesoridazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Mesoridazine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Escitalopram.Approved, Investigational
EsmololMesoridazine may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Mesoridazine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Mesoridazine.Approved
EthanolMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mesoridazine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Mesoridazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mesoridazine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Mesoridazine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Mesoridazine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Mesoridazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Mesoridazine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Mesoridazine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Mesoridazine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mesoridazine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Mesoridazine.Approved, Illicit, Investigational
GepefrineMesoridazine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Mesoridazine.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Mesoridazine can be increased when it is combined with Halofantrine.Approved
HaloperidolThe metabolism of Mesoridazine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Hexobarbital.Approved
HydrocodoneMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mesoridazine.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
HydroxyamphetamineMesoridazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Mesoridazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Iloperidone.Approved
ImipramineThe metabolism of Mesoridazine can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Indalpine.Investigational, Withdrawn
IndenololMesoridazine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Mesoridazine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Indiplon.Investigational
Iofetamine I-123Mesoridazine may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Mesoridazine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Mesoridazine.Approved, Vet Approved
IsoniazidThe metabolism of Mesoridazine can be decreased when combined with Isoniazid.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Mesoridazine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Mesoridazine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolMesoridazine may increase the hypotensive activities of Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Lamotrigine.Approved, Investigational
LandiololMesoridazine may increase the hypotensive activities of Landiolol.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levetiracetam.Approved, Investigational
LevobunololMesoridazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Mesoridazine can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mesoridazine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Mesoridazine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Mesoridazine.Approved, Investigational
LisdexamfetamineMesoridazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Mesoridazine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Lofentanil.Illicit
LopinavirThe metabolism of Mesoridazine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Mesoridazine.Approved
LorcaserinThe metabolism of Mesoridazine can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Mesoridazine.Approved
LumefantrineThe serum concentration of Mesoridazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Mesoridazine.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineThe metabolism of Mesoridazine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Mesoridazine can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Melperone.Approved, Investigational
MephedroneMesoridazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineMesoridazine may decrease the stimulatory activities of Mephentermine.Approved
MepindololMesoridazine may increase the hypotensive activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Mesoridazine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Meptazinol.Experimental
MequitazineMesoridazine may increase the arrhythmogenic activities of Mequitazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Metaxalone.Approved
MethadoneThe metabolism of Mesoridazine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMesoridazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Mesoridazine.Approved
MethotrimeprazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMesoridazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Mesoridazine.Approved
MetipranololMesoridazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Mesoridazine.Approved, Investigational
MetoprololThe metabolism of Mesoridazine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineMesoridazine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Mesoridazine.Approved, Illicit
MidomafetamineMesoridazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Mesoridazine can be decreased when combined with Midostaurin.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Investigational
MirabegronThe metabolism of Mesoridazine can be decreased when combined with Mirabegron.Approved
MirtazapineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MizoribineThe serum concentration of Mesoridazine can be increased when it is combined with Mizoribine.Investigational
MMDAMesoridazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Mesoridazine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Mesoridazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Investigational
NadololMesoridazine may increase the hypotensive activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mesoridazine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Mesoridazine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Mesoridazine.Approved, Withdrawn
NevirapineThe metabolism of Mesoridazine can be decreased when combined with Nevirapine.Approved
NicardipineThe metabolism of Mesoridazine can be decreased when combined with Nicardipine.Approved
NicomorphineMesoridazine may increase the hypotensive activities of Nicomorphine.Experimental
NilotinibThe metabolism of Mesoridazine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Mesoridazine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Mesoridazine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Mesoridazine.Approved
OpiumThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Opium.Approved, Illicit
OrphenadrineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Mesoridazine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Mesoridazine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mesoridazine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mesoridazine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Mesoridazine.Approved
PanobinostatThe serum concentration of Mesoridazine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe metabolism of Mesoridazine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Mesoridazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololMesoridazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mesoridazine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Mesoridazine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Mesoridazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Mesoridazine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Mesoridazine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Mesoridazine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Phenoxyethanol.Approved
PhentermineMesoridazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Mesoridazine.Approved
PindololMesoridazine may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pipotiazine.Approved, Investigational
PiribedilThe therapeutic efficacy of Mesoridazine can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pomalidomide.Approved
PractololMesoridazine may increase the hypotensive activities of Practolol.Approved
PramipexoleMesoridazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Mesoridazine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Mesoridazine.Approved
PrimaquineThe serum concentration of Mesoridazine can be increased when it is combined with Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Mesoridazine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Mesoridazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mesoridazine.Approved, Vet Approved
ProguanilThe serum concentration of Mesoridazine can be increased when it is combined with Proguanil.Approved
PromazineThe metabolism of Mesoridazine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Mesoridazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Mesoridazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Propoxycaine.Approved
PropranololMesoridazine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Mesoridazine is combined with PSD502.Investigational
PseudoephedrineMesoridazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe serum concentration of Mesoridazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Mesoridazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Mesoridazine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Mesoridazine.Approved
QuinacrineThe serum concentration of Mesoridazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Mesoridazine.Approved
QuinidineThe metabolism of Mesoridazine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Mesoridazine can be increased when it is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Raclopride.Investigational
RadicicolThe serum concentration of Mesoridazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Mesoridazine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Mesoridazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mesoridazine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Mesoridazine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mesoridazine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Mesoridazine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ritanserin.Investigational
RitobegronMesoridazine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Mesoridazine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Mesoridazine.Approved
RolapitantThe metabolism of Mesoridazine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Romifidine.Vet Approved
RopiniroleMesoridazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Mesoridazine.Approved
RotigotineMesoridazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Mesoridazine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Mesoridazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Mesoridazine.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Mesoridazine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Mesoridazine.Approved, Vet Approved
SinefunginThe serum concentration of Mesoridazine can be increased when it is combined with Sinefungin.Experimental
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
SotalolMesoridazine may increase the hypotensive activities of Sotalol.Approved
StiripentolThe metabolism of Mesoridazine can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mesoridazine.Approved, Investigational
SulfadoxineThe serum concentration of Mesoridazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of Mesoridazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulpirideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Mesoridazine.Approved, Investigational
SuvorexantMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
tafenoquineThe serum concentration of Mesoridazine can be increased when it is combined with tafenoquine.Investigational
TalinololMesoridazine may increase the hypotensive activities of Talinolol.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Mesoridazine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Mesoridazine.Approved
TerbinafineThe metabolism of Mesoridazine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TertatololMesoridazine may increase the hypotensive activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Mesoridazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tetrodotoxin.Investigational
ThalidomideMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Mesoridazine can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Mesoridazine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Mesoridazine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tilidine.Experimental
TimololMesoridazine may increase the hypotensive activities of Timolol.Approved
TipranavirThe metabolism of Mesoridazine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mesoridazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Mesoridazine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Mesoridazine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mesoridazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Mesoridazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Mesoridazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Mesoridazine.Approved, Investigational
VenlafaxineThe metabolism of Mesoridazine can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Vilazodone.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Mesoridazine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Mesoridazine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Mesoridazine.Approved, Investigational
ZolpidemMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Mesoridazine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Mesoridazine.Approved, Investigational
Food Interactions
  • Take with food to reduce irritation.

References

Synthesis Reference
US3084161
General References
Not Available
External Links
Human Metabolome Database
HMDB15068
KEGG Drug
D02671
KEGG Compound
C07143
PubChem Compound
4078
PubChem Substance
46506724
ChemSpider
3936
BindingDB
50131440
ChEBI
6780
ChEMBL
CHEMBL1088
Therapeutic Targets Database
DAP000252
PharmGKB
PA450386
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Mesoridazine
ATC Codes
N05AC03 — Mesoridazine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral25 mg
TabletOral50 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0767 mg/mLALOGPS
logP3.83ALOGPS
logP3.57ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)19.36ChemAxon
pKa (Strongest Basic)8.19ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity115.13 m3·mol-1ChemAxon
Polarizability43.83 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9322
Blood Brain Barrier+0.9863
Caco-2 permeable+0.5609
P-glycoprotein substrateSubstrate0.7284
P-glycoprotein inhibitor IInhibitor0.8978
P-glycoprotein inhibitor IIInhibitor0.5334
Renal organic cation transporterInhibitor0.7467
CYP450 2C9 substrateNon-substrate0.7962
CYP450 2D6 substrateNon-substrate0.5465
CYP450 3A4 substrateSubstrate0.5561
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5635
Ames testNon AMES toxic0.6982
CarcinogenicityNon-carcinogens0.8829
BiodegradationNot ready biodegradable0.9954
Rat acute toxicity2.7465 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7565
hERG inhibition (predictor II)Inhibitor0.762
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0002-9331000000-8e14cb597ee411174c3e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0119000000-fffe496e2ff640e0c935

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Piperidines / Benzenoids / 1,4-thiazines / Trialkylamines / Sulfoxides / Sulfinyl compounds / Azacyclic compounds / Organopnictogen compounds
show 2 more
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / Para-thiazine / Piperidine / Benzenoid / Sulfoxide / Tertiary amine
show 13 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, tertiary amino compound, sulfoxide (CHEBI:6780)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR: Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. Epub 2005 Aug 31. [PubMed:16135699]
  3. Choi S, Haggart D, Toll L, Cuny GD: Synthesis, receptor binding and functional studies of mesoridazine stereoisomers. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4379-82. [PubMed:15357957]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Choi S, Haggart D, Toll L, Cuny GD: Synthesis, receptor binding and functional studies of mesoridazine stereoisomers. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4379-82. [PubMed:15357957]
  2. Rauser L, Savage JE, Meltzer HY, Roth BL: Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther. 2001 Oct;299(1):83-9. [PubMed:11561066]
  3. Herrick-Davis K, Grinde E, Teitler M: Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther. 2000 Oct;295(1):226-32. [PubMed:10991983]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:44